Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447 Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]
Lire la suiteCommon neural signatures of psychedelics : Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition Selen Atasoy, Jakub Vohryzek, Gustavo Deco, Robin L. Carhart-Harris, Morten L. Kringelbach Progress in Brain Research, 2018, Volume 242,97- https://doi.org/10.1016/bs.pbr.2018.08.009 ISSN 0079-6123 © 2018 Elsevier B.V. All rights reserved. Abstract The search for the universal laws of human brain function is still on-going but progress is being made. Here we describe the novel concepts of connectome harmonics and connectomeharmonic decomposition, which can be used to characterize the brain activity associated with any mental state. We use this new frequency-specific language to describe the brain activity elicited by psilocybin and LSD [...]
Lire la suiteUne université de Houston teste la psilocybine pour la dépression résistante aux traitements - www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]
Lire la suiteBook Review : The psychedelic religion of mystical consciousness, Rick Strassman William A. Richards Sacred Knowledge: Psychedelics and Religious Experiences Columbia University Press, New York, 2016, 244 pp. Hardback ISBN: 978-0-231-17406-0 Journal of Psychedelic Studies, 2018 Doi : 10.1556/2054.2018.003 With an extreme range of terms for psychedelic drugs – from “schizotoxic” to “entheogenic” – “psychedelic,” nonetheless remains the most salient one. These substances manifest or disclose aspects of the mind of those who take them as well as the mind of those who study them. Proponents for the innumerable terms for these drugs are all able to adduce supportive evidence. Necessarily, this evidence is a subjective experience, [...]
Lire la suitePsilocybin exerts distinct effects on resting state networks 1 associated with serotonin and dopamine in mice Joanes Grandjean, David Buehlmann, Michaela Buerge, Hannes Sigrist, Erich Seifritz, Franz X. Vollenweider, Christopher R. Pryce, Markus Rudin Preprint · September 2019 Doi : 10.1101/751255 Abstract Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the default-mode network (DMN), a constellation of inter-connected regions that is involved in self-reference and displays altered FC in depressive disorders. In this study we investigated the effects of psilocybin on FC in the analogue of the [...]
Lire la suiteLe microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche Vittorio Biancardi Revue CIRCE, 2019, 11, Résumé Le micro-dosage est un phénomène social de plus en plus répandu parmi la communauté des consommateurs et consommatrices des substances dites psychédéliques. Il consiste une consommation d’un dixième de la dose typique de substance (principalement LSD ou Psilocybine) de façon fréquente, deux ou trois fois par semaine, pour améliorer les capacités cognitives ou comme auto-thérapie. L’analyse de ce phénomène est actuellement très fragmentaire et inconsistante, tant du point de vue des sciences humaines que du point de vue des sciences dites «dures». L’objectif de [...]
Lire la suiteScientists mass-produce 'magic mushroom' active ingredient from bacteria The study shows that psilocybin can be produced in a sustainable manner. https://www.zmescience.com/medicine/scientists-mass-produce-magic-mushroom-active-ingredient-from-bacteria/ byTibi Puiu October 3, 2019 Psilocybin, the active psychoactive compound found in specific mushrooms, is a promising drug that can be used to treat depression, anxiety, addiction, and post-traumatic stress disorder. Looking towards the future, researchers at Miami University have used genetic engineering to coax harmless E. coli bacteria to produce psilocybin. Psilocybe semilanceata. Credit: Pixabay. The mushrooms that produce psilocybin, such as Psilocybe cubensis, are not particularly expensive or difficult to grow. However, they do take up a lot of space and require many [...]
Lire la suitePsychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteLes psychédéliques peuvent-ils traiter l'anorexie et la dépression ? RESPADD, Actualités des Addictions, n°102, septembre 2019 Depuis son enfance, Rachael Petersen a vécu avec un sentiment de chagrin inexplicable qu'aucune pharmacothérapie ou psychothérapie n’a pu entièrement atténuer. Aussi, en 2017, elle s'est portée volontaire pour participer à un petit essai clinique à l'Université Johns Hopkins, qui testait la psilocybine, l'ingrédient actif des champignons hallucinogènes, pour le traitement de la dépression chronique. «J'étais tellement déprimée», a récemment déclaré Petersen, 29 ans. «J’ai eu l’impression que le monde m’avait abandonné, que j’avais perdu le droit d’exister sur cette planète. Vraiment, c’était comme si mes [...]
Lire la suiteThe Past and Future of Psychedelic Science : An Introduction to This Issue Richard E. Doblin, Merete Christiansen, Lisa Jerome, Brad Burge JOURNAL OF PSYCHOACTIVE DRUGS, 2019, VOL. 51, NO. 2, 93–97 https://doi.org/10.1080/02791072.2019.1606472 ABSTRACT Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and ‘60s, psychedelic research was [...]
Lire la suite